{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:21:24Z","timestamp":1782890484290,"version":"3.54.5"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13046-019-1212-1","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T15:04:22Z","timestamp":1558105462000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The kinase inhibitor SI113 induces autophagy and synergizes with quinacrine in hindering the growth of human glioblastoma multiforme cells"],"prefix":"10.1186","volume":"38","author":[{"given":"Silvia","family":"Matteoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Abbruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Matarrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Mileo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Miccadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Schenone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Musumeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias L.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Sette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine M.","family":"Carapella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Perrotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Signore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9445-442X","authenticated-orcid":false,"given":"Marco G.","family":"Paggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,17]]},"reference":[{"issue":"10","key":"1212_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396. \n                    https:\/\/doi.org\/10.1056\/NEJMoa043330\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"7580","key":"1212_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature16071","volume":"528","author":"M Osswald","year":"2015","unstructured":"Osswald M, Jung E, Sahm F, Solecki G, Venkataramani V, Blaes J, et al. Brain tumour cells interconnect to a functional and resistant network. Nature. 2015;528(7580):93\u20138. \n                    https:\/\/doi.org\/10.1038\/nature16071\n                    \n                  .","journal-title":"Nature"},{"issue":"7","key":"1212_CR3","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1021\/ci500235f","volume":"54","author":"F Ortuso","year":"2014","unstructured":"Ortuso F, Amato R, Artese A, D'Antona L, Costa G, Talarico C, et al. In silico identification and biological evaluation of novel selective serum\/glucocorticoid-inducible kinase 1 inhibitors based on the pyrazolo-pyrimidine scaffold. J Chem Inf Model. 2014;54(7):1828\u201332. \n                    https:\/\/doi.org\/10.1021\/ci500235f\n                    \n                  .","journal-title":"J Chem Inf Model"},{"issue":"5","key":"1212_CR4","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1159\/000374008","volume":"35","author":"L D'Antona","year":"2015","unstructured":"D'Antona L, Amato R, Talarico C, Ortuso F, Menniti M, Dattilo V, et al. SI113, a specific inhibitor of the Sgk1 kinase activity that counteracts cancer cell proliferation. Cell Physiol Biochem. 2015;35(5):2006\u201318. \n                    https:\/\/doi.org\/10.1159\/000374008\n                    \n                  .","journal-title":"Cell Physiol Biochem"},{"issue":"35","key":"1212_CR5","doi-asserted-by":"publisher","first-page":"37511","DOI":"10.18632\/oncotarget.5527","volume":"6","author":"C Talarico","year":"2015","unstructured":"Talarico C, D'Antona L, Scumaci D, Barone A, Gigliotti F, Fiumara CV, et al. Preclinical model in HCC: the SGK1 kinase inhibitor SI113 blocks tumor progression in vitro and in vivo and synergizes with radiotherapy. Oncotarget. 2015;6(35):37511\u201325. \n                    https:\/\/doi.org\/10.18632\/oncotarget.5527\n                    \n                  .","journal-title":"Oncotarget."},{"issue":"2","key":"1212_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ccell.2016.06.004","volume":"30","author":"P Castel","year":"2016","unstructured":"Castel P, Ellis H, Bago R, Toska E, Razavi P, Carmona FJ, et al. PDK1-SGK1 signaling sustains AKT-independent mTORC1 activation and confers resistance to PI3Kalpha inhibition. Cancer Cell. 2016;30(2):229\u201342. \n                    https:\/\/doi.org\/10.1016\/j.ccell.2016.06.004\n                    \n                  .","journal-title":"Cancer Cell"},{"key":"1212_CR7","doi-asserted-by":"publisher","first-page":"45361","DOI":"10.1038\/srep45361","volume":"7","author":"V Dattilo","year":"2017","unstructured":"Dattilo V, D'Antona L, Talarico C, Capula M, Catalogna G, Iuliano R, et al. SGK1 affects RAN\/RANBP1\/RANGAP1 via SP1 to play a critical role in pre-miRNA nuclear export: a new route of epigenomic regulation. Sci Rep. 2017;7:45361. \n                    https:\/\/doi.org\/10.1038\/srep45361\n                    \n                  .","journal-title":"Sci Rep"},{"key":"1212_CR8","doi-asserted-by":"publisher","unstructured":"Spagnuolo R, Dattilo V, D'Antona L, Cosco C, Tallerico R, Ventura V, et al. Deregulation of SGK1 in ulcerative colitis: a paradoxical relationship between immune cells and colonic epithelial cells. Inflamm Bowel Dis. 2018. \n                    https:\/\/doi.org\/10.1093\/ibd\/izy158\n                    \n                  .","DOI":"10.1093\/ibd\/izy158"},{"issue":"1","key":"1212_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1756-9966-31-4","volume":"31","author":"C Abbruzzese","year":"2012","unstructured":"Abbruzzese C, Mattarocci S, Pizzuti L, Mileo AM, Visca P, Antoniani B, et al. Determination of SGK1 mRNA in non-small cell lung cancer samples underlines high expression in squamous cell carcinomas. J Exp Clin Cancer Res. 2012;31(1):4. \n                    https:\/\/doi.org\/10.1186\/1756-9966-31-4\n                    \n                  .","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"1212_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1517\/13543784.2013.778971","volume":"22","author":"F Lang","year":"2013","unstructured":"Lang F, Voelkl J. Therapeutic potential of serum and glucocorticoid inducible kinase inhibition. Expert Opin Investig Drugs. 2013;22(6):701\u201314. \n                    https:\/\/doi.org\/10.1517\/13543784.2013.778971\n                    \n                  .","journal-title":"Expert Opin Investig Drugs"},{"key":"1212_CR11","doi-asserted-by":"publisher","unstructured":"Abbruzzese C, Matteoni S, Persico M, Ascione B, Schenone S, Musumeci F, et al. The small molecule SI113 hinders epithelial-to-mesenchymal transition and subverts cytoskeletal organization in human cancer cells. J Cell Physiol. 2019;Accepted for publication. \n                    https:\/\/doi.org\/10.1002\/jcp.28816\n                    \n                  .","DOI":"10.1002\/jcp.28816"},{"issue":"13","key":"1212_CR12","doi-asserted-by":"publisher","first-page":"15868","DOI":"10.18632\/oncotarget.7520","volume":"7","author":"C Talarico","year":"2016","unstructured":"Talarico C, Dattilo V, D'Antona L, Barone A, Amodio N, Belviso S, et al. SI113, a SGK1 inhibitor, potentiates the effects of radiotherapy, modulates the response to oxidative stress and induces cytotoxic autophagy in human glioblastoma multiforme cells. Oncotarget. 2016;7(13):15868\u201384. \n                    https:\/\/doi.org\/10.18632\/oncotarget.7520\n                    \n                  .","journal-title":"Oncotarget"},{"issue":"67","key":"1212_CR13","doi-asserted-by":"publisher","first-page":"110743","DOI":"10.18632\/oncotarget.22500","volume":"8","author":"C Abbruzzese","year":"2017","unstructured":"Abbruzzese C, Catalogna G, Gallo E, di Martino S, Mileo AM, Carosi M, et al. The small molecule SI113 synergizes with mitotic spindle poisons in arresting the growth of human glioblastoma multiforme. Oncotarget. 2017;8(67):110743\u201355. \n                    https:\/\/doi.org\/10.18632\/oncotarget.22500\n                    \n                  .","journal-title":"Oncotarget."},{"issue":"1","key":"1212_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13046-017-0642-x","volume":"36","author":"C Abbruzzese","year":"2017","unstructured":"Abbruzzese C, Matteoni S, Signore M, Cardone L, Nath K, Glickson JD, et al. Drug repurposing for the treatment of glioblastoma multiforme. J Exp Clin Cancer Res. 2017;36(1):169. \n                    https:\/\/doi.org\/10.1186\/s13046-017-0642-x\n                    \n                  .","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"1212_CR15","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/onc.2014.16","volume":"34","author":"M Pierobon","year":"2015","unstructured":"Pierobon M, Wulfkuhle J, Liotta L, Petricoin E. Application of molecular technologies for phosphoproteomic analysis of clinical samples. Oncogene. 2015;34(7):805\u201314. \n                    https:\/\/doi.org\/10.1038\/onc.2014.16\n                    \n                  .","journal-title":"Oncogene."},{"key":"1212_CR16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/978-1-60327-216-2_14","volume":"823","author":"M Pierobon","year":"2012","unstructured":"Pierobon M, Vanmeter AJ, Moroni N, Galdi F, Petricoin EF 3rd. Reverse-phase protein microarrays. Methods Mol Biol. 2012;823:215\u201335. \n                    https:\/\/doi.org\/10.1007\/978-1-60327-216-2_14\n                    \n                  .","journal-title":"Methods Mol Biol"},{"issue":"5","key":"1212_CR17","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1136\/gutjnl-2016-312623","volume":"67","author":"G Manic","year":"2018","unstructured":"Manic G, Signore M, Sistigu A, Russo G, Corradi F, Siteni S, et al. CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. Gut. 2018;67(5):903\u201317. \n                    https:\/\/doi.org\/10.1136\/gutjnl-2016-312623\n                    \n                  .","journal-title":"Gut."},{"issue":"4","key":"1212_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/BF00756761","volume":"10","author":"W Malorni","year":"1994","unstructured":"Malorni W, Rainaldi G, Rivabene R, Santini MT. Different susceptibilities to cell death induced by t-butylhydroperoxide could depend upon cell histotype-associated growth features. Cell Biol Toxicol. 1994;10(4):207\u201318.","journal-title":"Cell Biol Toxicol"},{"issue":"3","key":"1212_CR19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1750-3639.1999.tb00536.x","volume":"9","author":"N Ishii","year":"1999","unstructured":"Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC, et al. Frequent co-alterations of TP53, p16\/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 1999;9(3):469\u201379.","journal-title":"Brain Pathol"},{"issue":"8","key":"1212_CR20","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1593\/neo.09436","volume":"11","author":"SH Vellanki","year":"2009","unstructured":"Vellanki SH, Grabrucker A, Liebau S, Proepper C, Eramo A, Braun V, et al. Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia. 2009;11(8):743\u201352.","journal-title":"Neoplasia"},{"issue":"7","key":"1212_CR21","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1038\/sj.cdd.4401872","volume":"13","author":"A Eramo","year":"2006","unstructured":"Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ. 2006;13(7):1238\u201341. \n                    https:\/\/doi.org\/10.1038\/sj.cdd.4401872\n                    \n                  .","journal-title":"Cell Death Differ"},{"key":"1212_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/srep21557","volume":"6","author":"G Marziali","year":"2016","unstructured":"Marziali G, Signore M, Buccarelli M, Grande S, Palma A, Biffoni M, et al. Metabolic\/proteomic signature defines two glioblastoma subtypes with different clinical outcome. Sci Rep. 2016;6:21557. \n                    https:\/\/doi.org\/10.1038\/srep21557\n                    \n                  .","journal-title":"Sci Rep"},{"issue":"38","key":"1212_CR23","doi-asserted-by":"publisher","first-page":"4572","DOI":"10.1038\/onc.2012.470","volume":"32","author":"R Amato","year":"2013","unstructured":"Amato R, Scumaci D, D'Antona L, Iuliano R, Menniti M, Di Sanzo M, et al. Sgk1 enhances RANBP1 transcript levels and decreases taxol sensitivity in RKO colon carcinoma cells. Oncogene. 2013;32(38):4572\u20138. \n                    https:\/\/doi.org\/10.1038\/onc.2012.470\n                    \n                  .","journal-title":"Oncogene."},{"issue":"3","key":"1212_CR24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cell.2010.01.028","volume":"140","author":"N Mizushima","year":"2010","unstructured":"Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell. 2010;140(3):313\u201326. \n                    https:\/\/doi.org\/10.1016\/j.cell.2010.01.028\n                    \n                  .","journal-title":"Cell."},{"issue":"1","key":"1212_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13048-016-0239-6","volume":"9","author":"A Fransson","year":"2016","unstructured":"Fransson A, Glaessgen D, Alfredsson J, Wiman KG, Bajalica-Lagercrantz S, Mohell N. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant high-grade serous ovarian cancer. J Ovarian Res. 2016;9(1):27. \n                    https:\/\/doi.org\/10.1186\/s13048-016-0239-6\n                    \n                  .","journal-title":"J Ovarian Res"},{"key":"1212_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/1756-9966-32-72","volume":"32","author":"A Garufi","year":"2013","unstructured":"Garufi A, Trisciuoglio D, Porru M, Leonetti C, Stoppacciaro A, D'Orazi V, et al. A fluorescent curcumin-based Zn (II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells. J Exp Clin Cancer Res. 2013;32:72. \n                    https:\/\/doi.org\/10.1186\/1756-9966-32-72\n                    \n                  .","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"1212_CR27","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1158\/0008-5472.CAN-08-3014","volume":"69","author":"J Copp","year":"2009","unstructured":"Copp J, Manning G, Hunter T. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res. 2009;69(5):1821\u20137. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-3014\n                    \n                  .","journal-title":"Cancer Res"},{"issue":"3","key":"1212_CR28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1042\/BJ20081668","volume":"416","author":"JM Garcia-Martinez","year":"2008","unstructured":"Garcia-Martinez JM, Alessi DR. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J. 2008;416(3):375\u201385. \n                    https:\/\/doi.org\/10.1042\/BJ20081668\n                    \n                  .","journal-title":"Biochem J"},{"issue":"12","key":"1212_CR29","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00109-009-0525-5","volume":"87","author":"R Amato","year":"2009","unstructured":"Amato R, D'Antona L, Porciatti G, Agosti V, Menniti M, Rinaldo C, et al. Sgk1 activates MDM2-dependent p53 degradation and affects cell proliferation, survival, and differentiation. J Mol Med (Berl). 2009;87(12):1221\u201339. \n                    https:\/\/doi.org\/10.1007\/s00109-009-0525-5\n                    \n                  .","journal-title":"J Mol Med (Berl)"},{"issue":"20","key":"1212_CR30","doi-asserted-by":"publisher","first-page":"11598","DOI":"10.1073\/pnas.181181198","volume":"98","author":"LD Mayo","year":"2001","unstructured":"Mayo LD, Donner DB. A phosphatidylinositol 3-kinase\/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A. 2001;98(20):11598\u2013603. \n                    https:\/\/doi.org\/10.1073\/pnas.181181198\n                    \n                  .","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1212_CR31","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1042\/BJ20041057","volume":"384","author":"JT Murray","year":"2004","unstructured":"Murray JT, Campbell DG, Morrice N, Auld GC, Shpiro N, Marquez R, et al. Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem J. 2004;384(Pt 3:477\u201388. \n                    https:\/\/doi.org\/10.1042\/BJ20041057\n                    \n                  .","journal-title":"Biochem J"},{"issue":"2","key":"1212_CR32","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.bbrc.2010.04.100","volume":"396","author":"Y Murakami","year":"2010","unstructured":"Murakami Y, Hosoi F, Izumi H, Maruyama Y, Ureshino H, Watari K, et al. Identification of sites subjected to serine\/threonine phosphorylation by SGK1 affecting N-myc downstream-regulated gene 1 (NDRG1)\/Cap43-dependent suppression of angiogenic CXC chemokine expression in human pancreatic cancer cells. Biochem Biophys Res Commun. 2010;396(2):376\u201381. \n                    https:\/\/doi.org\/10.1016\/j.bbrc.2010.04.100\n                    \n                  .","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1212_CR33","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1073\/pnas.1314469111","volume":"111","author":"M Weiler","year":"2014","unstructured":"Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, et al. mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Proc Natl Acad Sci U S A. 2014;111(1):409\u201314. \n                    https:\/\/doi.org\/10.1073\/pnas.1314469111\n                    \n                  .","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"172","key":"1212_CR34","doi-asserted-by":"publisher","first-page":"RE5","DOI":"10.1126\/stke.2003.172.re5","volume":"2003","author":"H Tran","year":"2003","unstructured":"Tran H, Brunet A, Griffith EC, Greenberg ME. The many forks in FOXO's road. Sci STKE. 2003;2003(172):RE5. \n                    https:\/\/doi.org\/10.1126\/stke.2003.172.re5\n                    \n                  .","journal-title":"Sci STKE"},{"issue":"8","key":"1212_CR35","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/bjc.2017.293","volume":"117","author":"W Liu","year":"2017","unstructured":"Liu W, Wang X, Liu Z, Wang Y, Yin B, Yu P, et al. SGK1 inhibition induces autophagy-dependent apoptosis via the mTOR-Foxo3a pathway. Br J Cancer. 2017;117(8):1139\u201353. \n                    https:\/\/doi.org\/10.1038\/bjc.2017.293\n                    \n                  .","journal-title":"Br J Cancer"},{"issue":"2","key":"1212_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088891","volume":"9","author":"S Mori","year":"2014","unstructured":"Mori S, Nada S, Kimura H, Tajima S, Takahashi Y, Kitamura A, et al. The mTOR pathway controls cell proliferation by regulating the FoxO3a transcription factor via SGK1 kinase. PLoS One. 2014;9(2):e88891. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0088891\n                    \n                  .","journal-title":"PLoS One"},{"issue":"3","key":"1212_CR37","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/onc.2017.334","volume":"37","author":"F Zhang","year":"2018","unstructured":"Zhang F, Virshup DM, Cheong JK. Oncogenic RAS-induced CK1alpha drives nuclear FOXO proteolysis. Oncogene. 2018;37(3):363\u201376. \n                    https:\/\/doi.org\/10.1038\/onc.2017.334\n                    \n                  .","journal-title":"Oncogene"},{"issue":"3","key":"1212_CR38","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1091\/mbc.01-05-0272","volume":"13","author":"M Los","year":"2002","unstructured":"Los M, Mozoluk M, Ferrari D, Stepczynska A, Stroh C, Renz A, et al. Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling. Mol Biol Cell. 2002;13(3):978\u201388. \n                    https:\/\/doi.org\/10.1091\/mbc.01-05-0272\n                    \n                  .","journal-title":"Mol Biol Cell"},{"issue":"7665","key":"1212_CR39","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature23275","volume":"548","author":"CS Zhang","year":"2017","unstructured":"Zhang CS, Hawley SA, Zong Y, Li M, Wang Z, Gray A, et al. Fructose-1,6-bisphosphate and aldolase mediate glucose sensing by AMPK. Nature. 2017;548(7665):112\u20136. \n                    https:\/\/doi.org\/10.1038\/nature23275\n                    \n                  .","journal-title":"Nature."},{"key":"1212_CR40","doi-asserted-by":"publisher","unstructured":"Prakasam G, Singh RK, Iqbal MA, Saini SK, Tiku AB, Bamezai RNK. Pyruvate kinase M knockdown-induced signaling via AMP-activated protein kinase promotes mitochondrial biogenesis, autophagy, and cancer cell survival. J Biol Chem. 2017;292(37):15561\u201376. \n                    https:\/\/doi.org\/10.1074\/jbc.M117.791343\n                    \n                  .","DOI":"10.1074\/jbc.M117.791343"},{"issue":"7400","key":"1212_CR41","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nature11066","volume":"485","author":"SM Jeon","year":"2012","unstructured":"Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature. 2012;485(7400):661\u20135. \n                    https:\/\/doi.org\/10.1038\/nature11066\n                    \n                  .","journal-title":"Nature."},{"issue":"2","key":"1212_CR42","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrm.2017.95","volume":"19","author":"S Herzig","year":"2018","unstructured":"Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018;19(2):121\u201335. \n                    https:\/\/doi.org\/10.1038\/nrm.2017.95\n                    \n                  .","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1212_CR43","doi-asserted-by":"publisher","unstructured":"Bartolome A, Garcia-Aguilar A, Asahara SI, Kido Y, Guillen C, Pajvani UB, et al. MTORC1 regulates both general autophagy and Mitophagy induction after oxidative phosphorylation uncoupling. Mol Cell Biol. 2017. \n                    https:\/\/doi.org\/10.1128\/MCB.00441-17\n                    \n                  .","DOI":"10.1128\/MCB.00441-17"},{"issue":"3","key":"1212_CR44","doi-asserted-by":"publisher","first-page":"E12","DOI":"10.3171\/2014.12.FOCUS14748","volume":"38","author":"EB Golden","year":"2015","unstructured":"Golden EB, Cho HY, Hofman FM, Louie SG, Schonthal AH, Chen TC. Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors. Neurosurg Focus. 2015;38(3):E12. \n                    https:\/\/doi.org\/10.3171\/2014.12.FOCUS14748\n                    \n                  .","journal-title":"Neurosurg Focus"},{"issue":"1","key":"1212_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/0008-5472.CAN-12-2464","volume":"73","author":"T Kimura","year":"2013","unstructured":"Kimura T, Takabatake Y, Takahashi A, Isaka Y. Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res. 2013;73(1):3\u20137. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2464\n                    \n                  .","journal-title":"Cancer Res"},{"issue":"1","key":"1212_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/onc.2015.99","volume":"35","author":"VW Rebecca","year":"2016","unstructured":"Rebecca VW, Amaravadi RK. Emerging strategies to effectively target autophagy in cancer. Oncogene. 2016;35(1):1\u201311. \n                    https:\/\/doi.org\/10.1038\/onc.2015.99\n                    \n                  .","journal-title":"Oncogene."},{"issue":"9","key":"1212_CR47","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nrc.2017.53","volume":"17","author":"JM Mulcahy Levy","year":"2017","unstructured":"Mulcahy Levy JM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17(9):528\u201342. \n                    https:\/\/doi.org\/10.1038\/nrc.2017.53\n                    \n                  .","journal-title":"Nat Rev Cancer"},{"key":"1212_CR48","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejphar.2015.12.017","volume":"771","author":"S Pascolo","year":"2016","unstructured":"Pascolo S. Time to use a dose of chloroquine as an adjuvant to anti-cancer chemotherapies. Eur J Pharmacol. 2016;771:139\u201344. \n                    https:\/\/doi.org\/10.1016\/j.ejphar.2015.12.017\n                    \n                  .","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"1212_CR49","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1001\/archderm.1980.01640290097026","volume":"116","author":"L Tanenbaum","year":"1980","unstructured":"Tanenbaum L, Tuffanelli DL. Antimalarial agents. Chloroquine, hydroxychloroquine, and quinacrine. Arch Dermatol. 1980;116(5):587\u201391.","journal-title":"Arch Dermatol"},{"key":"1212_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-016-0303-5","volume":"35","author":"Y Yan","year":"2016","unstructured":"Yan Y, Xu Z, Dai S, Qian L, Sun L, Gong Z. Targeting autophagy to sensitive glioma to temozolomide treatment. J Exp Clin Cancer Res. 2016;35:23. \n                    https:\/\/doi.org\/10.1186\/s13046-016-0303-5\n                    \n                  .","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"1212_CR51","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1159\/000373952","volume":"35","author":"C Li","year":"2015","unstructured":"Li C, Liu Y, Liu H, Zhang W, Shen C, Cho K, et al. Impact of autophagy inhibition at different stages on cytotoxic effect of autophagy inducer in glioblastoma cells. Cell Physiol Biochem. 2015;35(4):1303\u201316. \n                    https:\/\/doi.org\/10.1159\/000373952\n                    \n                  .","journal-title":"Cell Physiol Biochem"},{"key":"1212_CR52","doi-asserted-by":"publisher","unstructured":"Mulcahy Levy JM, Zahedi S, Griesinger AM, Morin A, Davies KD, Aisner DL, et al. Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors. Elife. 2017;6. \n                    https:\/\/doi.org\/10.7554\/eLife.19671\n                    \n                  .","DOI":"10.7554\/eLife.19671"},{"issue":"1","key":"1212_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15548627.2015.1100356","volume":"12","author":"DJ Klionsky","year":"2016","unstructured":"Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12(1):1\u2013222. \n                    https:\/\/doi.org\/10.1080\/15548627.2015.1100356\n                    \n                  .","journal-title":"Autophagy."},{"key":"1212_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2017.40","volume":"2","author":"JRD Pearson","year":"2017","unstructured":"Pearson JRD, Regad T. Targeting cellular pathways in glioblastoma multiforme. Signal Transduct Target Ther. 2017;2:17040. \n                    https:\/\/doi.org\/10.1038\/sigtrans.2017.40\n                    \n                  .","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"1212_CR55","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1172\/JCI34739","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008;118(9):3065\u201374. \n                    https:\/\/doi.org\/10.1172\/JCI34739\n                    \n                  .","journal-title":"J Clin Invest"},{"issue":"22","key":"1212_CR56","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/onc.2010.626","volume":"30","author":"V Serra","year":"2011","unstructured":"Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene. 2011;30(22):2547\u201357. \n                    https:\/\/doi.org\/10.1038\/onc.2010.626\n                    \n                  .","journal-title":"Oncogene"},{"issue":"12","key":"1212_CR57","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/nm.1890","volume":"14","author":"JA Engelman","year":"2008","unstructured":"Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008;14(12):1351\u20136. \n                    https:\/\/doi.org\/10.1038\/nm.1890\n                    \n                  .","journal-title":"Nat Med"},{"issue":"4","key":"1212_CR58","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1158\/1078-0432.CCR-14-1814","volume":"21","author":"PL Bedard","year":"2015","unstructured":"Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, et al. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1\/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res. 2015;21(4):730\u20138. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1814\n                    \n                  .","journal-title":"Clin Cancer Res"},{"key":"1212_CR59","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1517\/14728222.2011.639361","volume":"16","author":"A De Luca","year":"2012","unstructured":"De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N. The RAS\/RAF\/MEK\/ERK and the PI3K\/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Tar. 2012;16:S17\u201327. \n                    https:\/\/doi.org\/10.1517\/14728222.2011.639361\n                    \n                  .","journal-title":"Expert Opin Ther Tar"},{"issue":"8","key":"1212_CR60","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/s41419-018-0864-7","volume":"9","author":"M Buccarelli","year":"2018","unstructured":"Buccarelli M, Marconi M, Pacioni S, De Pasqualis I, D'Alessandris QG, Martini M, et al. Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis. Cell Death Dis. 2018;9(8):841. \n                    https:\/\/doi.org\/10.1038\/s41419-018-0864-7\n                    \n                  .","journal-title":"Cell Death Dis"},{"issue":"1","key":"1212_CR61","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-019-0720-y","volume":"12","author":"Y Mou","year":"2019","unstructured":"Mou Y, Wang J, Wu J, He D, Zhang C, Duan C, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12(1):34. \n                    https:\/\/doi.org\/10.1186\/s13045-019-0720-y\n                    \n                  .","journal-title":"J Hematol Oncol"},{"issue":"8","key":"1212_CR62","doi-asserted-by":"publisher","first-page":"853","DOI":"10.2174\/1389450116666150316223655","volume":"17","author":"Z Wang","year":"2016","unstructured":"Wang Z, Liu P, Chen Q, Deng S, Liu X, Situ H, et al. Targeting AMPK signaling pathway to overcome drug resistance for Cancer therapy. Curr Drug Targets. 2016;17(8):853\u201364.","journal-title":"Curr Drug Targets"},{"issue":"1","key":"1212_CR63","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13046-015-0221-y","volume":"34","author":"GJ Yoshida","year":"2015","unstructured":"Yoshida GJ. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res. 2015;34(1):111. \n                    https:\/\/doi.org\/10.1186\/s13046-015-0221-y\n                    \n                  .","journal-title":"J Exp Clin Cancer Res"},{"issue":"1\u20133","key":"1212_CR64","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1387\/ijdb.150082iv","volume":"59","author":"I Vitale","year":"2015","unstructured":"Vitale I, Manic G, Dandrea V, De Maria R. Role of autophagy in the maintenance and function of cancer stem cells. Int J Dev Biol. 2015;59(1\u20133):95\u2013108. \n                    https:\/\/doi.org\/10.1387\/ijdb.150082iv\n                    \n                  .","journal-title":"Int J Dev Biol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1212-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-019-1212-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1212-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T23:22:08Z","timestamp":1589584928000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-019-1212-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,17]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1212"],"URL":"https:\/\/doi.org\/10.1186\/s13046-019-1212-1","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,17]]},"assertion":[{"value":"15 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"202"}}